Pazopanib
Small molecule targets CSF1R, CYP2C8, CYP3A4, FGFR1, FGFR3, ITK, KIT, LCK, PDGFRA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | VOTRIENT | — | 2012-01-12 – 2014-11-18 | fda.gov ↗ |
| Approved | EU (EMA) | Votrient | — | 2010-06-14 | europa.eu ↗ |
| Approved | US (FDA) | VOTRIENT | — | 2009-10-19 | fda.gov ↗ |
Trials 242 · started per year
Also used as a comparator or background therapy in 25 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03275558 Comparator | Jul 2018 | gliosarcoma | Center Trials & Treatment | Withdrawn | No outcome recorded |
| Phase 1 | NCT02009449 Background | Nov 2013 → Feb 2019 | breast cancer, colorectal carcinoma, melanoma, non-small cell lung carcinoma +3 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00732420 Background | Sep 2008 → Jun 2013 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03628131 Background | Oct 2018 → Jul 2023 | childhood malignant neoplasm | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01975519 Background | Dec 2013 → Mar 2019 | soft tissue sarcoma | Tracon Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT02203760 Comparator | Oct 2019 → Dec 2024 overdue | female reproductive organ cancer | North Eastern German Society of Gynaecological Oncology | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02959554 Comparator | Dec 2016 → Aug 2020 | renal cell carcinoma | AIO-Studien-gGmbH | Terminated | No outcome recorded |
| Phase 2 | NCT03379012 Background | Feb 2016 → Jan 2018 | renal cell carcinoma | Kidney Cancer Research Bureau | Completed | No outcome recorded |
| Phase 2 | NCT02207309 Comparator | Jun 2015 → Jul 2016 | soft tissue sarcoma | Ludwig-Maximilians - University of Munich | Terminated | No outcome recorded |
| Phase 2 | NCT02187302 Comparator | Jul 2014 → Jul 2016 | renal cell carcinoma | NewLink Genetics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01813136 Comparator | Mar 2013 → Jan 2019 | thyroid gland carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 2 | NCT00430781 Comparator | Nov 2006 → Jul 2008 | cervical cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05432791 Comparator | Mar 2023 → Aug 2024 overdue | leiomyosarcoma of the corpus uteri | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT06726421 Background | Sep 2024 → Sep 2030 expected | renal cell carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06263231 Comparator | Jun 2024 → Dec 2027 expected | soft tissue sarcoma | Intensity Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04741438 Comparator | Mar 2021 → Feb 2025 | sarcoma | Centre Leon Berard | Unknown | No outcome recorded |
| Phase 3 | NCT03592472 Background | Jul 2018 → Dec 2026 expected | renal cell carcinoma | Xynomic Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT03260894 Comparator | Dec 2017 → Aug 2018 | renal cell carcinoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02049905 Comparator | Jan 2014 → May 2017 | soft tissue sarcoma | ImmunityBio, Inc. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT05949424 Comparator | May 2024 → Mar 2025 | breast carcinoma, endometrial carcinoma, ovarian carcinoma, renal cell carcinoma +1 | University Medical Center Groningen | Unknown | No outcome recorded |
| Phase 4 | NCT02555748 Comparator | Nov 2015 → Jan 2020 | renal cell carcinoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05816642 Comparator | Aug 2022 → Dec 2023 | renal cell carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT03571438 Comparator | Oct 2017 → Sep 2022 | kidney cancer | University Hospital, Grenoble | Unknown | No outcome recorded |
| — | NCT02208128 Comparator | May 2014 → Feb 2018 | renal cell carcinoma | Heidelberg University | Unknown | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02354612 Background | — | cancer | Tracon Pharmaceuticals Inc. | No longer available | No outcome recorded |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 274 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pazopanib | “GW786034 (Pazopanib) is an orally active, potent, reversible, small molecule tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2,...” NCT00158782 ↗262“Within the SOC arm, patients received single-agent bevacizumab (19), axitinib (18), everolimus (7), pazopanib (4), sorafenib (4), sunitinib (2), or temsirolimus (2).” PMID 28950297 ↗ Nov 2017 “Pazopanib is an oral chemotherapy and works by decreasing the blood supply to tumors which limits the tumor's source of oxygen and nutrients.” NCT01622660 ↗ “Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma” NCT00256880 ↗ “pazopanib hydrochloride (pazopanib)” NCT01664182 ↗ “Paclitaxel, Pazopanib, Pentostatin” NCT02788201 ↗ “Sunitinib, Sorafenib or Pazopanib” NCT01731158 ↗ “Paclitaxel Pazopanib Pentostatin” NCT02551718 ↗ “GW786034 (pazopanib)” NCT00401583 ↗ “KIT - Pazopanib” NCT02645149 ↗ |
| Known as | GW-786034B | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | GW786034 | “A Phase II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Pazopanib (GW786034) as Neoadjuvant Therapy in Treatment-Naïve Subjects With Stage IA, IB, IIA or...” NCT00367679 ↗33“A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma included 19 patients after a maximum of 2 lines of chemotherapy for...” NCT01498458 ↗ “Pazopanib (GW-786034) is a second-generation multitargeted tyrosine kinase inhibitor against VEGFR-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-alpha, PDGFR-beta...” PMID 18230058 ↗ Feb 2008 “I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid cancers.” NCT00625846 ↗ “The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.” PMID 22014006 ↗ Oct 2011 “Pilot Study of GW786034 (Pazopanib), a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Operable Breast Cancer” NCT00450879 ↗ “A Randomized, Phase II Study of GW786034 (Pazopanib) in Stage D0 Relapsed Androgen Sensitive Prostate Cancer Following Limited GnRH Agonist Therapy” NCT00454571 ↗ “Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma” PMID 20200024 ↗ Mar 2010 “A Phase 2 Study of GW786034 (Pazopanib) With or Without Bicalutamide in Hormone Refractory Prostate Cancer” NCT00486642 ↗ “Phase II Trial of Pazopanib (GW786034) in Pre-Treated and Untreated Metastatic Melanoma Patients” NCT00861913 ↗ “Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma” NCT00334282 ↗ “Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma” NCT00256880 ↗ “single dose of Pazopanib (GW786034) Administered as Eye Drops” NCT00659555 ↗ “pazopanib (pazopanib hydrochloride) (GW786034)” NCT01340794 ↗ “Adjuvant Pazopanib (GW786034) Versus Placebo” NCT00775307 ↗ “GW786034 (Pazopanib; NSC-737754; IND-XXXX)” NCT00788580 ↗ “Pazopanib (GW786034)(GW786034)” NCT00674024 ↗ “Doses of Pazopanib (GW786034)” NCT00861029 ↗ “pazopanib (GW786034) 400 mg” NCT00347919 ↗ “Drug: pazopanib (GW786034)” NCT00561795 ↗ “Drug: Pazopanib (GW786034)” NCT00722293 ↗ “Pazopanib (GW786034)” NCT00549328 ↗ “pazopanib (GW786034)” NCT00430781 ↗ “Pazopanib (GW786034)” NCT00945477 ↗ “Pazopanib (GW786034)” NCT01130623 ↗ “Pazopanib (GW786034)” NCT00363194 ↗ “Pazopanib (GW786034)” NCT01049776 ↗ “Pazopanib (GW786034)” NCT00678977 ↗ |
| Known as | NSC-737754 | “A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors” NCT01956669 ↗1“GW786034 (Pazopanib; NSC-737754; IND-XXXX)” NCT00788580 ↗ |
| Known as | NSC-752782 | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | paz | “Pazopanib (paz) is a potent small molecular inhibitor of VEGF-1, -2, -3, PDGFR, c-kit, and has activity as a single agent in ovarian cancer.” PMID 32247603 ↗ Apr 2020 |
| Known as | Pazopanib (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | Pazopanib (GW786034) | “Pazopanib (GW786034)” NCT01385228 ↗ |
| Known as | Pazopanib (GW786034; Votrient) | “Pazopanib (GW786034; Votrient®)” NCT01577784 ↗ |
| Known as | Pazopanib hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | pazopanib hydrochloride | “To assess the safety and tolerability of GSK2118436 (dabrafenib) given with pazopanib (pazopanib hydrochloride) as well as determining the maximum tolerated dosing regimen in...” NCT01713972 ↗22“The purpose of this study is to find out what effects pazopanib (pazopanib hydrochloride) (also called Votrient®) may have on MRI (magnetic resonance imaging) scans, blood...” NCT01599832 ↗ “I. To establish the safety and efficacy of GW786034 (pazopanib hydrochloride) as a therapeutic in patients afflicted with differentiated, medullary and anaplastic thyroid cancers.” NCT00625846 ↗ “Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.” NCT01402271 ↗ “Determine the maximum tolerated dose (MTD) of temozolomide and pazopanib (pazopanib hydrochloride) combination in patients with advanced PNET.” NCT01465659 ↗ “This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced angiosarcoma.” NCT01462630 ↗ “Giving pazopanib hydrochloride together with bicalutamide may be an effective treatment for prostate cancer.” NCT00486642 ↗ “pazopanib (pazopanib hydrochloride) as 3rd-line therapy in metastatic renal cell carcinoma (mRCC) patients” NCT01157091 ↗ “pazopanib (pazopanib hydrochloride) plus oral topotecan (topotecan hydrochloride).” NCT02357810 ↗ “daily oral GW786034 (pazopanib hydrochloride) for at least 12 consecutive days” NCT00450879 ↗ “Patients receive oral pazopanib hydrochloride once daily on days 1-28.” NCT00471536 ↗ “treatment with pazopanib (pazopanib hydrochloride) versus placebo” NCT01841736 ↗ “Patients receive oral pazopanib hydrochloride daily on days 1-28.” NCT01208064 ↗ “pazopanib (pazopanib hydrochloride) (GW786034)” NCT01340794 ↗ “oral pazopanib hydrochloride once daily” NCT00788580 ↗ “pazopanib hydrochloride (pazopanib)” NCT01664182 ↗ “Drug: Pazopanib Hydrochloride” NCT01767636 ↗ “Drug: Pazopanib Hydrochloride” NCT00454363 ↗ “Drug: Pazopanib Hydrochloride” NCT01552356 ↗ “Drug: Pazopanib Hydrochloride” NCT01532687 ↗ “Drug: Pazopanib Hydrochloride” NCT02180867 ↗ “Drug: Pazopanib Hydrochloride” NCT02601209 ↗ “Drug: Pazopanib Hydrochloride” NCT01446809 ↗ |
| Known as | Pazopanib is marketed as Votrient. | “Pazopanib is marketed as Votrient.” NCT01265940 ↗ |
| Known as | Pazopanib monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL477772 ↗ |
| Known as | Pazopanib monohydrochloride salt GW786034 | “Pazopanib monohydrochloride salt GW786034” NCT01049776 ↗ |
| Known as | PZP | “Association of Bevacizumab (BVC)+ Pazopanib (PZP)” NCT01202032 ↗ |
| Known as | Votrient | “The patient was enrolled in a clinical trial and treated with an anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a multikinase VEGF inhibitor (pazopanib/Votrient®).” PMID 26062823 ↗ Jun 20154“The study involves the drugs Pazopanib (Votrient), Gemcitabine (Gemzar), and Docetaxel (Taxotere).” NCT01593748 ↗ “Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL)” NCT00388076 ↗ “Pazopanib Oral Tablet [Votrient]” NCT04741438 ↗ |
| Known as | Votrient (Pazopanib hydrochloride) | “Votrient (Pazopanib hydrochloride)” NCT01472081 ↗ |
| Action | Inhibit | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL477772 ↗5“Fibroblast growth factor receptor 3 inhibitor” CHEMBL477772 ↗ “Fibroblast growth factor receptor 1 inhibitor” CHEMBL477772 ↗ “Tyrosine-protein kinase ITK/TSK inhibitor” CHEMBL477772 ↗ “Tyrosine-protein kinase LCK inhibitor” CHEMBL477772 ↗ “tyrosine kinase inhibitor” NCT00158782 ↗ |
| Modality | Small molecule | “small molecule” NCT00158782 ↗ |
| Route | Oral | “Patients receive oral GW786034 twice daily.” NCT00060151 ↗ |
| Target | CSF1R | “Macrophage colony stimulating factor receptor inhibitor” CHEMBL477772 ↗ |
| Target | CYP2C8 | “pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4” PMID 24800949 ↗ May 2014 |
| Target | CYP3A4 | “pazopanib and lapatinib, weak inhibitors of CYP2C8 and CYP3A4” PMID 24800949 ↗ May 2014 |
| Target | FGFR1 | “Fibroblast growth factor receptor 1 inhibitor” CHEMBL477772 ↗ |
| Target | FGFR3 | “Fibroblast growth factor receptor 3 inhibitor” CHEMBL477772 ↗ |
| Target | ITK | “Tyrosine-protein kinase ITK/TSK inhibitor” CHEMBL477772 ↗ |
| Target | LCK | “Tyrosine-protein kinase LCK inhibitor” CHEMBL477772 ↗ |